Published in Curr Neuropharmacol on December 01, 2011
Repeated variate stress in male rats induces increased voiding frequency, somatic sensitivity, and urinary bladder nerve growth factor expression. Am J Physiol Regul Integr Comp Physiol (2013) 0.94
CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons. Neurosci Lett (2013) 0.80
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn (2002) 22.80
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem (2003) 8.83
Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci (2003) 7.44
The nerve growth factor 35 years later. Science (1987) 7.25
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol (2006) 7.13
Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol (2000) 6.31
The yin and yang of neurotrophin action. Nat Rev Neurosci (2005) 4.45
The neural control of micturition. Nat Rev Neurosci (2008) 4.19
Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci (2006) 3.44
NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J (2005) 3.21
Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev (2004) 3.08
BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem (2007) 2.96
New words for old: lower urinary tract symptoms for "prostatism". BMJ (1994) 2.60
Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience (1994) 2.36
The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int (2005) 2.31
A role for BDNF in mechanosensation. Nat Neurosci (1998) 2.08
Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci (2005) 2.06
Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol (2000) 2.01
Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol (2010) 1.96
Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol (2008) 1.96
Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol (1997) 1.85
Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci (1997) 1.84
Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J Physiol (2003) 1.84
Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci (1999) 1.77
BDNF as a pain modulator. Prog Neurobiol (2008) 1.73
Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci (2001) 1.62
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience (2000) 1.56
Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc Natl Acad Sci U S A (1999) 1.50
Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci (2006) 1.48
Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) (2006) 1.48
Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest (1991) 1.47
Current and future pharmacological treatment for overactive bladder. J Urol (2002) 1.47
Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol (2006) 1.46
Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol (2006) 1.44
The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem (2001) 1.43
Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol (2001) 1.41
Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol (2002) 1.41
Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. J Neurosci (2003) 1.40
BDNF in sensory neurons and chronic pain. Neurosci Res (2006) 1.38
Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions. Am J Pathol (1999) 1.37
Inflammatory pain: the cellular basis of heat hyperalgesia. Curr Neuropharmacol (2006) 1.37
Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci (2004) 1.30
Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons. Neuroscience (1996) 1.25
Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain (1996) 1.24
Nociceptor-derived brain-derived neurotrophic factor regulates acute and inflammatory but not neuropathic pain. Mol Cell Neurosci (2006) 1.24
Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol (2004) 1.24
Modulation of temperature-sensitive TRP channels. Semin Cell Dev Biol (2006) 1.24
Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci (2003) 1.23
The role of nerve growth factor in a model of visceral inflammation. Neuroscience (1997) 1.23
Noxious stimulation induces Trk receptor and downstream ERK phosphorylation in spinal dorsal horn. Mol Cell Neurosci (2002) 1.22
Blockade of NGF and trk receptors inhibits increased peripheral mechanical sensitivity accompanying cystitis in rats. Am J Physiol Regul Integr Comp Physiol (2008) 1.21
BDNF: a neuromodulator in nociceptive pathways? Brain Res Brain Res Rev (2002) 1.21
The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol (2001) 1.19
Increased nerve growth factor expression triggers bladder overactivity. J Pain (2004) 1.18
Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol (2006) 1.15
Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. Br J Anaesth (1999) 1.15
Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol (2008) 1.12
Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol (2007) 1.11
Brain-derived neurotrophic factor induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. Eur J Neurosci (2004) 1.10
Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J Urol (2005) 1.10
Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain (2002) 1.10
Overactive bladder: an update. Curr Opin Urol (2007) 1.08
Cranial sensory neuron development in the absence of brain-derived neurotrophic factor in BDNF/Bax double null mice. Dev Biol (2004) 1.05
Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology (2001) 1.05
Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways. J Comp Neurol (2002) 1.03
Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur J Neurosci (1998) 1.02
Visceral pain. Br J Anaesth (1995) 1.00
Effects of trkB and trkC neurotrophin receptor agonists on thermal nociception: a behavioral and electrophysiological study. Pain (1999) 0.99
Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol (1996) 0.97
Up-regulation of tyrosine kinase (Trka, Trkb) receptor expression and phosphorylation in lumbosacral dorsal root ganglia after chronic spinal cord (T8-T10) injury. J Comp Neurol (2002) 0.97
Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn (2007) 0.95
Autocrine nerve growth factor in human keratinocytes. J Dermatol Sci (2000) 0.95
Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience (2002) 0.95
Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn (2008) 0.92
Neurotrophins in spinal cord nociceptive pathways. Prog Brain Res (2004) 0.92
A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology (2003) 0.91
Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience (2010) 0.90
The sensory mechanotransduction ion channel ASIC2 (acid sensitive ion channel 2) is regulated by neurotrophin availability. Neuroscience (2005) 0.89
Inflammation causes expression of NGF in epithelial cells of the rat colon. Exp Neurol (2008) 0.88
Cellular and subcellular colocalization of nerve growth factor and epidermal growth factor in mouse submandibular glands. Anat Rec (1985) 0.87
Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk. Br J Pharmacol (2007) 0.85
Development and neuronal dependence of cutaneous sensory nerve formations: Lessons from neurotrophins. Microsc Res Tech (2010) 0.84
Brain-derived neurotrophic factor induces NMDA receptor 1 phosphorylation in rat spinal cord. Neuroreport (2002) 0.83
Expression of BDNF and TrkB in mouse taste buds after denervation and in circumvallate papillae during development. Arch Histol Cytol (2003) 0.81
Hypertrophy and reversal of hypertrophy in rat pelvic ganglion neurons. J Neurocytol (1992) 0.81
Nerve growth factor concentration in human saliva. Oral Dis (2007) 0.80
Pacinian corpuscle development involves multiple Trk signaling pathways. Dev Dyn (2004) 0.80
Efferent and afferent neuronal hypertrophy associated with micturition pathways in spontaneously hypertensive rats. Neurourol Urodyn (1997) 0.79
Nerve growth factor. Science (1975) 0.77
Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur Urol (2008) 2.13
EAU guidelines on surgical treatment of urinary incontinence. Eur Urol (2012) 2.05
Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int (2010) 2.03
Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol (2010) 1.96
Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol (2012) 1.67
Exploratory study assessing efficacy and complications of TVT-O, TVT-Secur, and Mini-Arc: results at 12-month follow-up. Eur Urol (2011) 1.65
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Intermediate-term results, up to 4 years, of a bone-anchored male perineal sling for treating male stress urinary incontinence after prostate surgery. BJU Int (2008) 1.50
The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol (2002) 1.49
Co-administration of transient receptor potential vanilloid 4 (TRPV4) and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis. BJU Int (2015) 1.43
Biomarkers in lower urinary tract symptoms/overactive bladder: a critical overview. Curr Opin Urol (2014) 1.43
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. Mediators Inflamm (2011) 1.42
Suburethral single incision slings in the treatment of female stress urinary incontinence: what is the evidence for using them in 2010? Arch Esp Urol (2011) 1.42
TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med (2006) 1.34
TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.31
Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci (2004) 1.30
EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol (2012) 1.23
Association of traffic-related air pollution with cognitive development in children. J Epidemiol Community Health (2009) 1.22
Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol (2009) 1.19
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm (2010) 1.17
Selective alterations within executive functions in adolescents with excess weight. Obesity (Silver Spring) (2010) 1.17
A role for iron in an ancient carbonic anhydrase. J Biol Chem (2003) 1.13
Spinal cord injury and bladder dysfunction: new ideas about an old problem. ScientificWorldJournal (2011) 1.07
Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. Pain (2005) 1.06
Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type 2) diabetic rats. Med Sci Monit (2007) 1.04
Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. Eur J Neurosci (2005) 1.02
Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int (2006) 1.02
Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. J Urol (2009) 1.02
Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol (2011) 1.01
Anti-inflammatory effect of lycopene on carrageenan-induced paw oedema and hepatic ischaemia-reperfusion in the rat. Br J Nutr (2009) 1.01
Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovasc Diabetol (2013) 1.00
Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol (2009) 1.00
GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol (2008) 0.99
Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. J Urol (2007) 0.99
Antihyperglycaemic and protective effects of flavonoids on streptozotocin-induced diabetic rats. Phytother Res (2010) 0.98
Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU Int (2004) 0.98
The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr Neuropharmacol (2007) 0.94
Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol (2012) 0.93
Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Exp Neurol (2008) 0.93
[Accuracy of magnetic resonance cholangiopancreatography for the diagnosis of common bile duct stones]. Rev Med Chil (2008) 0.91
Portal biliopathy: a multitechnique imaging approach. Abdom Imaging (2012) 0.91
Neurochemical characterization of insulin receptor-expressing primary sensory neurons in wild-type and vanilloid type 1 transient receptor potential receptor knockout mice. J Comp Neurol (2007) 0.91
Impact of preoperative ultrasonographic staging of the neck in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg (2007) 0.91
Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. Mediators Inflamm (2013) 0.91
Prenatal DHA status and neurological outcome in children at age 5.5 years are positively associated. J Nutr (2011) 0.91
Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study. Eur Urol (2004) 0.90
Neurotrophins as regulators of urinary bladder function. Nat Rev Urol (2012) 0.90
Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol (2014) 0.90
Botulinum toxin treatment for bladder dysfunction. Int J Urol (2013) 0.89
An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine (2011) 0.89
Acute transient myopia with shallowing of the anterior chamber induced by sulfamethoxazole in a patient with pseudoxanthoma elasticum. J Glaucoma (2014) 0.88
Quality of life of rural menopausal women in response to a customized exercise programme. J Adv Nurs (2006) 0.87
Structures of the iron-sulfur flavoproteins from Methanosarcina thermophila and Archaeoglobus fulgidus. J Bacteriol (2005) 0.87
Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. BJU Int (2012) 0.87
Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother (2012) 0.87
The activation of the ERK pathway contributes to the spinal c-fos expression observed after noxious bladder stimulation. Somatosens Mot Res (2007) 0.87
Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biol Ther (2009) 0.86
Short-term assessment of a tension-free vaginal tape for treating female stress urinary incontinence. BJU Int (2009) 0.86
Characterization of VEGF and angiopoietins expression in human corpus cavernosum during aging. J Sex Med (2010) 0.86
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Curr Opin Urol (2014) 0.86
Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic sports doping. Cardiovasc Toxicol (2009) 0.85
The novel PARP inhibitor 5-aminoisoquinolinone reduces the liver injury caused by ischemia and reperfusion in the rat. Med Sci Monit (2002) 0.85
Bioactivity studies and chemical profile of the antidiabetic plant Genista tenera. J Ethnopharmacol (2008) 0.85
The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. Eur Urol (2005) 0.85
Single-incision sling system as primary treatment of female stress urinary incontinence: prospective 12 months data from a single institution. BJU Int (2011) 0.85
Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol (2012) 0.84
Insulin induces cobalt uptake in a subpopulation of rat cultured primary sensory neurons. Eur J Neurosci (2003) 0.84
Differential effects of acute (extenuating) and chronic (training) exercise on inflammation and oxidative stress status in an animal model of type 2 diabetes mellitus. Mediators Inflamm (2011) 0.84
Junctional adhesion molecule-A regulates cell migration and resistance to shear stress. J Cell Physiol (2006) 0.84
Prenatal exposure to mirex impairs neurodevelopment at age of 4 years. Neurotoxicology (2009) 0.84
Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol (2005) 0.83
Effect of angiogenesis-related cytokines on rotator cuff disease: the search for sensitive biomarkers of early tendon degeneration. Clin Med Insights Arthritis Musculoskelet Disord (2011) 0.83
[Pathological characteristics of thyroid microcarcinoma. A review of 402 biopsies]. Rev Med Chil (2005) 0.82
Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol (2009) 0.82
An ultrasound model to discriminate the risk of thyroid carcinoma. Acad Radiol (2010) 0.82
Bladder sensory desensitization decreases urinary urgency. BMC Urol (2007) 0.82
N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology (2008) 0.81
Effect of onabotulinumtoxinA on intramural parasympathetic ganglia: an experimental study in the guinea pig bladder. J Urol (2012) 0.81
Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int (2011) 0.81
Does baseline total testosterone improve the yielding of prostate cancer screening? Eur J Cancer (2012) 0.80
VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCG. BMC Physiol (2011) 0.80
Overactive bladder: pathophysiology, diagnostics, and therapies. Adv Urol (2012) 0.80
Cystitis is associated with TRPV1b-downregulation in rat dorsal root ganglia. Neuroreport (2008) 0.80
Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat. Inflammation (2015) 0.80
Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. Exp Neurol (2006) 0.80
Lipid mediator profiles differ between lung compartments in asthmatic and healthy humans. Eur Respir J (2013) 0.80
Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. Handb Exp Pharmacol (2011) 0.80
Epithelioid hemangioendothelioma presenting as a vertebral fracture. Acta Reumatol Port (2010) 0.80